Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214766 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
A Phase 1 study of Healthy Participants, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 312
- Enrollment target
- 4
- Study locations
NCT07214766 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Genentech. The registered enrollment target is 312 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (395% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT07214766, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 312 participants
- Enrollment target
- 4
- Study locations
Study Summary
This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).
Conditions Studied
Interventions
- DRUG Trastuzumab
Study Locations (4)
California
- Anaheim Clinical Trials - Anaheim
Florida
- Daytona Beach Clinical Rsch Unit - Daytona Beach
Missouri
- QPS Bio-Kinetic - Springfield
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214766
The ClinicalTrials.gov registry entry for NCT07214766 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (395% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab is the first listed.
NCT07214766 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT07214766 about?
NCT07214766 is a clinical study titled "A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants". This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).
What is the current status of trial NCT07214766?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2025-10-17. Estimated completion is 2026-04-15.
What conditions does trial NCT07214766 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07214766?
The interventions under investigation include: Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT07214766?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214766 being conducted?
This trial has 4 study locations across California, Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
-
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.